Shafrin: VBAs ‘Will Never Make Up a Majority of Reimbursement’

May 27, 2020

Healthcare economist Jason Shafrin says that while value-based agreements can be useful in a number of situations, they won’t have significant play in drug reimbursement.

Shafrin points to a recent paper on value-based agreements by Dubois, Westrich and Buelt.

“In short, VBAs are a useful tool in some situations—perhaps gene therapies where outcomes are easily observable and treatment costs are high—but due to the administrative cost and implementation challenges, they will never make up the majority of drug reimbursement,” Shafrin writes.

Read more on Healthcare Economist, click here.

Share This Story!